Holistic Litigation Strategies for Strengthening or Defeating a Written Description Invalidity Defense

April 26, 2022 9:15am

John Haberman
Senior Director, IP
Sarepta Therapeutics

Steven M. Coyle
Partner
Cantor Colburn LLP

Matthew Pearson
Partner
Akin Gump Strauss Hauer & Feld LLP

Kevin S. Prussia
Partner
Wilmer Cutler Pickering Hale and Dorr LLP

Moderator:

Vanessa Yen
Partner
King & Spalding LLP

  • Reviewing Biogen International GMBH v. Mylan Pharmaceuticals Inc. Appeal No. 20-1933, where the Federal Circuit affirmed invalidity of a method of treatment patent for lack of written description
  • Appreciating the importance of inventor testimony and the impact of post-filing clinical data
    • When can witness admissions strengthen a written description invalidity defense?
  • Identifying when to divide your opponent’s testimony between IPR proceedings and district court litigation
  • Considering the dissent and determining whether the district court erred in applying judicial estoppel